Tecentriq Hybreza

Active Ingredient(s): Atezolizumab + Hyaluronidase-tqjs
FDA Approved: * September 12, 2024
Pharm Company: * GENENTECH INC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Tecentriq Hybreza Subcutaneous Injection
NDC: 50242-933
Labeler:
Genentech, Inc.

Related Brands

Drugs with the same active ingredients